Thaysen has had to deal with orchestrating Illumina’s comeback strategy and the loose ends related to unwinding the company’s failed $7.1 billion acquisition of Grail. The early stage blood ...

In a report released today, Eve Burstein from Bernstein maintained a Hold rating on Illumina (ILMN – Research Report), with a price target of ...

Negative Revenue Trend: Examining Illumina's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.6% in revenue growth ...

China accounts for roughly 7 ... Illumina’s stock was trading at $131 per share at the start of the year. But since China placed it on the unreliable list last month, the stock has declined ...

China accounts for about 7% of Illumina's sales. Gene sequencers help determine the sequence of DNA or RNA, allowing scientists to study genetic variations associated with diseases and diagnose ...

Here are the biggest headlines of the day in the latest Market Minute. Illumina (ILMN) shares have recouped their losses. The stock had fallen after China banned it from exporting its gene ...

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...

In 2024, the UCITS C-share USD returned 14.7% net of fees, while the MSCI ACWI ... Brown Advisors Global Leaders Strategy emphasized stocks such as Illumina, Inc. (NASDAQ:ILMN).

Illumina is the world’s leading producer of gene-sequencing machines and counts on China for 7 percent of its sales. Beijing also said it took action against dozens of other companies from the ...

In 2020, Illumina announced that it had reached an agreement with Grail for an acquisition worth $7.1 billion. Illumina completed the deal just under a year later, bringing Grail back under its ...